Shares of Home Depot Inc. (NYSE: HD) were up slightly on Wednesday. The stock has dropped 8% over the past 12 months. The home improvement retailer is scheduled to report its fourth quarter 2022 earnings results on Tuesday, February 21, before market open. Here’s a look at what to expect from the report:
Analysts expect Home Depot to deliver revenue of $36 billion for the fourth quarter of 2022. This compares to $35.7 billion reported in the same period last year. In the third quarter of 2022, sales increased 5.6% year-over-year to $38.9 billion.
Analysts are projecting EPS of $3.27 for Home Depot in Q4. This compares to EPS of $3.21 in the year-ago period. In Q3 2022, EPS increased 8% YoY to $4.24.
Points to note
In the third quarter of 2022, Home Depot’s comparable sales increased 4.3% while comparable sales in the US grew 4.5%. The company benefited from solid demand for home improvement projects and saw growth from both its Pro and DIY customers. Despite some softness in certain products and categories, the project business remained strong across most departments.
In Q3, inflation across product categories and demand for new products helped drive an 8.8% increase in comp average ticket. However, comp transactions dropped 4.4%.
The company delivered positive comps across most of its merchandising departments and with the momentum in the project business, it recorded double-digit comps in areas like building materials, plumbing and lumber. Sales growth in the Pro segment outpaced the DIY segment in Q3. Home Depot has seen encouraging trends from its larger Pro customers who posted double-digit comps in Q3. This momentum is likely to have continued through the fourth quarter. In its last quarterly call, the company said its Pro customers have solid backlogs. Home Depot believes there will continue to be strong demand for home improvement over the long term.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic chimeric antigen receptor (CAR) T-cell therapy products for
Cintas Corp. (CTAS) Q3 2023 earnings and revenue increase
Uniform rental company Cintas Corporation (NASDAQ: CTAS) on Wednesday announced financial results for the third quarter of 2023, reporting higher earnings and revenues. At $2.19 billion, third-quarter revenues were up
Infographic: Micron (MU) reports net loss for Q2; revenue down 53%
Micron Technology Inc. (NASDAQ: MU) slipped to a loss in the second quarter of 2023 from a profit last year, hurt by a sharp fall in revenues. The chipmaker reported